Hemophilia Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Hemophilia Epidemiology Forecast Report Coverage

Expert Market Research's “Hemophilia Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of hemophilia. It projects the future incidence and prevalence rates of hemophilia cases across various populations.  The study covers age and type as major determinants of the hemophilia population. The report highlights patterns in the prevalence of hemophilia over time and projects future trends based on multiple variables.

Hemophilia Understanding: Disease Overview

Hemophilia is a rare blood disorder characterized by an increased risk of bleeding or bruising. It occurs due to the limited amount of clotting factors present in the blood. Hemophilia is classified into several types and may be mild, moderate, or severe depending on the levels of clotting factor in the blood. Acquired hemophilia is rare in occurrence but can happen when autoantibodies start attacking a specific clotting factor.

The most significant symptom observed in hemophilic patients is excessive or unusual bleeding or bruising. Common hemophilia symptoms include easy bruising, prolonged bleeding, and painful joint bleeds (hemarthrosis). The condition is typically diagnosed through blood tests that measure clotting factor levels.

Hemophilia Epidemiology Perspective

The hemophilia epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the hemophilia epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Hemophilia B and its trends. The hemophilia detailed epidemiology segmentation is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Hemophilia A is the most common hemophilia type, with the Centers for Disease Control and Prevention (CDC) estimates showing that 10 in 100,000 individuals  are affected by the condition. 
• In the United States, 3 out of 100,000 people have hemophilia B, whereas hemophilia C affects 1 in 100,000 people .
• According to the National Institute for Health and Care Excellence (NICE ), 2,069 individuals in the United Kingdom were living with hemophilia B in 2022/2023. Among them, 374 had the severe form of the condition, while 351 were classified as having a moderate form.
• India has the second-largest population of hemophilia patients globally, with an estimated 136,000 cases of hemophilia A , as per the Haemophilia and Health Collective of North (HHCN).

Age-Based Hemophilia Epidemiology Insights

Many cases of hemophilia are diagnosed in children before they turn 2 years of age , and in up to two-thirds of cases, there is a family history of hemophilia involved. According to CDC data, individuals with mild hemophilia are typically diagnosed at a median age of 36 months, while those with moderate hemophilia are diagnosed at 8 months, and those with severe hemophilia are diagnosed at a median age of just 1 month.

Gender-Based Hemophilia Epidemiology Insights

A study conducted in the United States and published in Haemophilia (2021) revealed that severe or moderate hemophilia in women is uncommon due to the X-linked recessive inheritance pattern of the condition, which primarily affects males. However, nearly 1 out of 5 patients  with mild hemophilia were reported to be women.

Read more about this report - Request a Free Sample

Country-wise Hemophilia Epidemiology Segment

The hemophilia epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of hemophilia varies between countries owing to differences in genetic factors, healthcare infrastructure, diagnostic capabilities, public health awareness, and socioeconomic conditions. From April 2022 to March 2023 inclusive, 6,662 and 1,342 males  were documented to have hemophilia A and B, respectively, in the United Kingdom, as reported by the United Kingdom Haemophilia Centres Doctors’ Organisation (2023).

Hemophilia: Treatment Overview

Treatment for hemophilia usually involves the replacement of the missing clotting factor in the blood, which is done by injecting clotting factor concentrates or other medications. Clotting factor concentrates are commercially prepared concentrates that are administered intravenously. Emicizumab, desmopressin, and tranexamic acid are some of the hemophilia therapeutics.

Recent advancements include extended half-life clotting factors, which reduce how often infusions are needed, and non-factor therapies like emicizumab, a monoclonal antibody used for hemophilia A. Gene therapy has also emerged as a promising hemophilia treatment option that can offer long-term correction by enabling the body to produce its own clotting factors.

Key Questions Answered

• What are the key findings of hemophilia epidemiology in the 8 major markets?
• What will be the total number of patients with hemophilia across the 8 major markets during the forecast period?
• What was the country-wise hemophilia epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of hemophilia cases during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of hemophilia during the forecast period of 2026-2035?
• What are the currently available treatments in the global hemophilia market?
• What are the disease risks, signs, symptoms, and unmet needs of hemophilia?

Scope of the Hemophilia Epidemiology Report

• The hemophilia epidemiology forecast covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Hemophilia B based on several factors.
• The Hemophilia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The hemophilia report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Global Haemophilia Treatment Market Report and Forecast

Hemophilia B Epidemiology Forecast